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ALI = acute lung injury; ARDS = acute respiratory distress syndrome; IκB = inhibitory protein κB; NF-κB = nuclear factor κB; PaCO2 = arterial
carbon dioxide tension; THAM = tris-hydroxymethyl aminomethane; VALI = ventilator-associated lung injury.
Available online http://ccforum.com/content/9/1/51
Introduction
Current protective lung ventilation strategies generally involve
some degree of hypercapnia. This has resulted in a shift in
clinical paradigms regarding hypercapnia from avoidance to
tolerance, with hypercapnia increasingly permitted in order to
realize the benefits of low lung stretch. Insights from
laboratory models of acute lung injury (ALI) have suggested
that hypercapnia may play an active role in the pathogenesis
of inflammation and tissue injury. This raises the possibility
that hypercapnia per se may exert direct protective effects in
ALI states, distinct from the demonstrated benefits of
reduced lung stretch. However, there are no clinical data
evaluating the efficacy of hypercapnia per se, independent of
ventilator strategy, in ALI states. Furthermore, it is unlikely that
a clinical trial of ‘permissive hypercapnia’ will be carried out,
at least in the medium term.
This article reviews the current clinical status of permissive
hypercapnia, discusses insights gained to date from basic
scientific studies of hypercapnia and acidosis, and considers
the potential clinical implications of these findings for the
management of patients with ALI.
Permissive hypercapnia: current paradigms
The potential for mechanical ventilation to potentiate or even
cause lung injury and worsen outcome in acute respiratory
distress syndrome (ARDS) patients is clear [1–3]. Ventilator-
associated lung injury (VALI) may occur via several
mechanisms. Mechanotrauma results from repetitive over-
stretching and damage to lung tissue, and cyclic alveolar
recruitment and derecruitment [4–9]. Increased mechanical
stress may directly activate the cellular and humoral immune
response in the lung [8–11], although the exact role played
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Abstract
Current protective lung ventilation strategies commonly involve hypercapnia. This approach has
resulted in an increase in the clinical acceptability of elevated carbon dioxide tension, with
hypoventilation and hypercapnia ‘permitted’ in order to avoid the deleterious effects of high lung
stretch. Advances in our understanding of the biology of hypercapnia have prompted consideration of
the potential for hypercapnia to play an active role in the pathogenesis of inflammation and tissue
injury. In fact, hypercapnia may protect against lung and systemic organ injury independently of
ventilator strategy. However, there are no clinical data evaluating the direct effects of hypercapnia per
se  in acute lung injury. This article reviews the current clinical status of permissive hypercapnia,
discusses insights gained to date from basic scientific studies of hypercapnia and acidosis, identifies
key unresolved concerns regarding hypercapnia, and considers the potential clinical implications for
the management of patients with acute lung injury.
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by this mechanism in the pathogenesis of lung and systemic
organ injury has been disputed [12,13]. In any case, the
potential for intrapulmonary prostaglandins [14], cytokines
[15], endotoxin [16] and bacteria [17] to cross an impaired
alveolar–capillary barrier following high stretch mechanical
ventilation is clear.
VALI may be limited by instituting protective lung ventilation
strategies in order to reduce mechanical trauma and the
resulting inflammatory effects. These strategies invariably
involve a reduction in the tidal volume and/or transalveolar
pressure, which generally leads to an elevation in arterial
carbon dioxide tension (PaCO2), an approach that has been
termed ‘permissive hypercapnia’. These protective lung
ventilation strategies have been demonstrated to improve
survival in patients with ARDS [1,18,19]. The reported levels
of PaCO2 and pH (mean maximum PaCO2 67 mmHg, mean
pH 7.2) in the study conducted Hickling and coworkers [18]
reflect typical levels observed with institution of this
technique. Accordingly, there has been a shift toward greater
clinical acceptability of hypercapnia in ALI and ARDS.
Current paradigms attribute the protective effect of these
ventilatory strategies solely to reductions in lung stretch, with
hypercapnia permitted in order to achieve this goal. However,
the potential exists for hypercapnia to modulate the
pathogenesis of VALI.
‘Bedside-to-bench’: rationale for laboratory
studies
Protective ventilatory strategies that involve hypoventilation
result in both limitation of tidal volume and elevation in
systemic carbon dioxide tension. Lung stretch is distinct from
elevated carbon dioxide tension, and by manipulation of
respiratory parameters (frequency, tidal volume, dead-space,
inspired carbon dioxide) it can, at least to some extent, be
separately controlled. The ARDSnet investigators reported a
25% reduction in mortality with a complex ventilation strategy
[20] involving limitation of mean tidal volume to 6 ml/kg, as
compared with a more traditional tidal volume of 12 ml/kg [2].
That study minimized the potential for hypercapnia in the low
tidal volume group, and instead permitted increased
respiratory rates (respiratory frequency of 29 breaths/min). In
fact, the need to reduce tidal volumes substantially to improve
outcome in ARDS patients was recently questioned [21,22],
and it is increasingly clear that most clinicians seldom use
very low tidal volumes in practice [23]. These findings raise
questions regarding the need for – and indeed the clinical
acceptability of – permissive hypercapnia.
These issues underscore the need to determine the effects of
hypercapnia in isolation. If hypercapnia were proven to have
independent benefit, then deliberately elevating PaCO2 could
confer an additional advantage over reducing lung stretch.
Conversely, in patients managed with conventional
permissive hypercapnia, adverse effects of elevated PaCO2
might be concealed by the benefits of lessened lung stretch.
Because outcome in the intensive care unit might be related
to systemic injury – as opposed to simply lung injury – it is
necessary to determine the effects of hypercapnia on
pathophysiological function in the heart and brain as well as
the lung. These issues are further underlined by the fact that
hypercapnia has potentially severe adverse effects in some
clinical settings, such as critically elevated intracranial
pressure or pulmonary vascular resistance.
It is not currently practicable or feasible to examine the direct
effects of hypercapnic acidosis, independent of ventilator
strategy, in humans. This has necessitated a return to the
laboratory bench, and an examination of the potential for
induced hypercapnia to modulate the severity of ALI and
systemic organ injury in animal models.
Hypercapnia and acidosis: insights from the
bench
There is a growing body of evidence suggesting that
hypercapnia and acidosis exert biologically important
beneficial effects in experimental ALI and systemic organ
injury. The mechanisms that underlie these protective effects
of hypercapnia are increasingly well characterized.
Acute lung injury
Direct administration of inspired carbon dioxide has been
demonstrated to attenuate ALI in several ex vivo and in vivo
laboratory models. In the isolated perfused rabbit lung,
hypercapnic acidosis was demonstrated to attenuate the
increases in lung permeability seen following free radical [24],
ischaemia/reperfusion [24,25] and ventilator-induced [26] ALI.
Hypercapnic acidosis directly attenuates indices of ALI such
as oxygenation, lung mechanics and lung permeability,
following  in vivo pulmonary [27] and mesenteric [28]
ischaemia/reperfusion. Hypercapnic acidosis also directly
protects against endotoxin-induced lung injury, a model of
sterile sepsis-induced ARDS [29]. Hypercapnic acidosis
attenuates pulmonary apoptosis, a mechanism of
programmed cell death, following pulmonary ischaemia/
reperfusion [27].
In most clinical scenarios, therapeutic intervention is only
possible after initiation of the injury process. The therapeutic
potential of hypercapnic acidosis is underlined by the finding
that it was effective when instituted after initiation of the lung
injury process, in the settings of both mesenteric ischaemia/
reperfusion and endotoxin-induced ALI models [28,29]. This
contrasts with many other initially promising experimental
strategies, which demonstrate potential when used before
the injury process but lose their effectiveness when utilized
after the development of organ injury.
The ability of hypercapnic acidosis to attenuate VALI directly
was examined in in vivo laboratory studies. Hypercapnic
acidosis has been demonstrated to attenuate physiological
and histological indices of lung injury induced by very high53
levels of lung stretch [30]. Hypercapnic acidosis exhibits
more modest protective effects in the context of more
clinically relevant tidal stretch [31]. However, hypercapnic
acidosis did not attenuate lung injury induced by surfactant
depletion, an atelectasis-prone model of ALI [32]. Taken
together, these findings suggest that, in VALI, hypercapnic
acidosis may attenuate the component of injury that is due to
lung stretch but not that due to collapse and re-expansion of
atelectatic lung.
Systemic organ injury
Patients with ARDS tend not to die from respiratory failure
per se but rather because of the development of multiorgan
failure [33]. Hence, any consideration of the potential effects
of hypercapnic acidosis in critical illness must include its
effects in extrapulmonary organs.
Hypercapnic acidosis appears to exert protective effects on
the myocardium. In the isolated heart, reperfusion with a
hypercapnic acidotic perfusate for a short period potentiates
recovery of myocardial function following prolonged cold
cardioplegic ischaemia [34]. Metabolic acidosis to an
equivalent pH also appears to exert protective effects in ex
vivo models [35], although this is disputed [34]. Kitakaze and
coworkers [36] found that reperfusions with both
hypercapnic and metabolic acidotic reperfusates were
equally effective in reducing infarct size in an in vivo canine
model of left anterior descending coronary artery ischaemia.
In the brain, hypercapnic acidosis attenuates hypoxic/
ischaemic brain injury in the immature rat [37,38]. Hyper-
capnic acidosis protects the porcine brain from hypoxia/
reoxygenation-induced injury [39] and attenuates neuronal
apoptosis [40]. Cortical brain homogenates develop fewer
free radicals and less lipid peroxidation when pH is lowered
by carbon dioxide than when it is lowered by hydrochloric
acid [41]. In isolated hepatocytes exposed to anoxia [42] and
chemical hypoxia [43], acidosis markedly delays the onset of
cell death. Correction of the pH actually accelerated cell
death. This phenomenon may represent a protective
adaptation against hypoxic and ischaemic stress. Isolated
renal cortical tubules exposed to anoxia have improved ATP
levels on reoxygenation at a pH of 6.9 when compared with
tubules incubated at a pH of 7.5 [42].
Dose–response issues
There is experimental evidence that the beneficial effects of
moderate hypercapnia may be counterbalanced by a
potential for adverse effects at higher levels. This is
supported by experimental evidence demonstrating that
protection from the adverse effects of brain ischaemia was
better when the inspired carbon dioxide was set at 6% rather
than at 9% [37]. Of concern, severe hypercapnia produced
by 15% carbon dioxide was more recently demonstrated to
worsen neurological injury in this context [44]. In isolated
hepatocytes, the degree of protection from anoxic injury
conferred by a metabolic acidosis was greater at a pH of 6.9
than at a pH of 6.6 [42].
Hypercapnia and acidosis: mechanisms of
action
A clear understanding of the cellular and biochemical
mechanisms that underlie the protective effects of hyper-
capnic acidosis is essential for several reasons. It constitutes
a prerequisite if translation of the laboratory findings to the
bedside is to be accomplished, because it allows us to define
more clearly the potential therapeutic utility of hypercapnic
acidosis in ALI. Of particular importance, a greater under-
standing of the mechanisms of action of hypercapnic acidosis
facilitates prediction of its potential side effects in the clinical
context. This may result in the identification of patient groups
for which hypercapnia may have deleterious effects and
should be avoided. Furthermore, it facilitates extrapolation of
these insights to a variety of other disease states. In this
regard, the finding that the protective effects of hypercapnic
acidosis in stretch-induced lung injury appear independent of
effects on surfactant [31] may have implications for
surfactant-deficient disease states such as infant respiratory
distress syndrome. Finally, a greater understanding of the
protective actions of hypercapnic acidosis in ALI may lead to
the discovery of other promising therapeutic modalities for
this devastating disease process.
Acidosis versus hypercapnia
The protective effects of hypercapnic acidosis may be a
function of the acidosis or the hypercapnia per se, or a
combination of both.  Acidosis is common in critical illness
and is often a poor prognostic sign. However, this effect is
associative rather than causative, and prognosis depends on
the underlying condition rather than on the acidosis per se.
This issue is of particular relevance when considering the
appropriateness of buffering in the clinical context. If any
protective effects of hypercapnic acidosis were found to
result from the acidosis, then efforts to buffer a hypercapnic
acidosis would lessen such protection and should be
discouraged. Conversely, if hypercapnia per se (and not the
acidaemia) were found to be protective, then further research
efforts should be directed to finding better buffering
strategies in order to maximize the benefits of hypercapnia.
The protective effects of hypercapnic acidosis in experimental
lung and systemic organ injury appear to be primarily a
function of the acidosis generated [25,45]. The myocardial
protective effects of hypercapnic acidosis are also seen with
metabolic acidosis both in ex vivo [35] and in vivo [36,46]
models. In the liver, acidosis delays the onset of cell death in
isolated anoxic hepatocytes [42,43,47]. However, the type of
acidosis (i.e. hypercapnic versus metabolic) does appear to
be of importance. Although normocapnic (i.e. metabolic)
acidosis attenuates primary ischaemia/reperfusion-induced
ALI in an ex vivo model, it is less effective than hypercapnic
acidosis [25]. In addition, there are reports of lung [48] and
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intestinal [49] injury following induction of metabolic acidosis
by hydrochloric acid infusion in whole animal models.
However, it is important to recognize that infusion of
hyperosmolar solutions of strong acids into whole animal
preparations may produce toxic effects that are unrelated to
any change in pH [50].
Conversely, in the isolated lung the protective effects of
hypercapnic acidosis in ischaemia/reperfusion-induced ALI
are greatly attenuated if the pH is buffered toward normal
[25]. Of concern, hypercapnia at normal pH may cause injury
to alveolar epithelial cell monolayers [45] and decrease
surfactant protein A function in vitro [51].
Anti-inflammatory effects
Several key components of the inflammatory response, which
contribute substantially to tissue injury and damage in ARDS
patients, appear to be attenuated by hypercapnic acidosis.
Hypercapnic acidosis appears to interfere with the
coordination of the immune response by reducing cytokine
signalling [52–54]. Hypercapnic acidosis inhibits the release
of tumour necrosis factor-α and interleukin-1 from stimulated
macrophages  in vitro [52]. The potential for hypercapnic
acidosis to attenuate pulmonary and systemic levels of key
cytokines in vivo is clear from the finding that it decreased
tumour necrosis factor-α levels in bronchoalveolar lavage
fluid following pulmonary ischaemia/reperfusion [27].
The cellular and molecular mechanisms that underlie the
inhibitory effects of hypercapnic acidosis in the neutrophil are
increasingly well understood. Hypercapnic acidosis
modulates neutrophil expression of selectins and intercellular
adhesion molecules, which are necessary for neutrophil
binding to the vascular surface during inflammation [55].
Hypercapnia and acidosis may impair neutrophil intracellular
pH regulation. Intracellular pH decreases when neutrophils
are activated by immune stimuli [56–59]. If milieu pH is
normal, then there tends to be a recovery in neutrophil
intracellular pH back toward normal levels. Hypercapnia
decreases extracellular and intracellular pH in the local milieu,
resulting in a rapid fall in neutrophil cytosolic pH [54,60,61],
potentially overwhelming the capacity of neutrophils, and in
particular activated neutrophils [62], to regulate cytosolic pH.
Failure to restore neutrophil cytosolic pH has been
demonstrated to impair functions such as chemotaxis
[63,64]. The potential for hypercapnic acidosis to attenuate
neutrophil activity in vivo is clear from the finding that it
attenuates lung neutrophil recruitment after both ventilator
induced [30] and endotoxin induced [29] ALI.
Effects on free radical generation and activity
Hypercapnic acidosis appears to attenuate free radical
production and modulate free radical induced tissue damage.
In common with most biological enzymes, the enzymes that
produce these oxidizing agents function optimally at neutral
physiological pH levels. Oxidant generation by both basal and
stimulated neutrophils appears to be regulated by ambient
carbon dioxide levels, with oxidant generation reduced by
hypercapnia and increased by hypocapnia [54]. The
production of superoxide by stimulated neutrophils in vitro is
decreased at acidic pH [65–67]. In the brain, hypercapnic
acidosis attenuates glutathione depletion and lipid
peroxidation, which are indices of oxidant stress [39]. In the
lung, hypercapnic acidosis has been demonstrated to reduce
free radical tissue injury following pulmonary ischaemia/
reperfusion [27]. Hypercapnic acidosis appears to attenuate
the production of higher oxides of nitric oxide, such as nitrite
and nitrate, following both ventilator-induced [26] and
endotoxin-induced [29] ALI. Hypercapnic acidosis inhibits
ALI mediated by xanthine oxidase, a complex enzyme system
produced in increased amounts during periods of tissue
injury, which is a potent source of free radicals [68] in the
isolated lung [24]. In in vitro studies the enzymatic activity of
xanthine oxidase was potently decreased by acidosis,
particularly hypercapnic acidosis [24,25].
Concerns exist regarding the potential for hypercapnia to
potentiate tissue nitration by peroxynitrite, a potent free
radical. Peroxynitrite is produced in vivo largely by the
reaction of nitric oxide with superoxide radical, and causes
tissue damage by oxidizing a variety of biomolecules and by
nitrating phenolic amino acid residues in proteins [69–73].
The potential for hypercapnia to promote the formation of
nitration products from peroxynitrite has been clearly
demonstrated in recent in vitro experiments [45,51].
However, the potential for hypercapnia to promote nitration of
lung tissue in vivo appears to depend on the injury process.
Hypercapnic acidosis decreased tissue nitration following
pulmonary ischaemia/reperfusion-induced ALI [27], but it
increased nitration following endotoxin-induced lung injury
[29].
Regulation of gene expression
Hypercapnic acidosis has been demonstrated to regulate the
expression of genes that are central to the inflammatory
response. Nuclear factor-κB (NF-κB) is a key regulator of the
expression of multiple genes that are involved in the
inflammatory response, and its activation represents a pivotal
early step in the activation of the inflammatory response [74].
NF-κB is found in the cytoplasm in an inactive form bound to
inhibitory proteins called inhibitory protein-κB (IκB), of which
the important isoforms are IκB-α and IκB-β. IκB proteins are
phosphorylated by the IκB kinase complex and subsequently
degraded, thus allowing NF-κB to translocate into the
nucleus, bind to specific promoter sites and activate target
genes [74]. Hypercapnic acidosis has been demonstrated to
inhibit significantly endotoxin-induced NF-κB activation and
DNA binding activity in human pulmonary endothelial cells via
a mechanism mediated through a decrease in IκB-α
degradation [75]. Hypercapnic acidosis was demonstrated to
suppress endothelial cell production of intercellular adhesion
molecule-1 and interleukin-8 mRNA and protein, which are
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thought to be mainly regulated by the NF-κB-related pathway,
and suppressed indices of cell injury [75].
‘Bench-to-bedside’: clinical implications
Permissive hypercapnia has become a central component of
protective lung ventilatory strategies, and is increasingly
accepted in the clinical context. Hypercapnia results in the
generation of an acidosis, the extent of which depends on the
degree of hypercapnia and whether buffering is practiced.
Although the presence of an acidosis, whether hypercapnic
or metabolic, indicates loss of physiological homeostasis and
the presence of disease and/or organ dysfunction, it
represents an association rather than a cause–effect
relationship, and it does not indicate that acidosis is directly
harmful. As discussed earlier, considerable experimental
evidence suggests the potential for hypercapnia and acidosis
to exert protective effects in the setting of ALI and systemic
organ injury. The mechanisms that underlie the effects of
hypercapnia are increasingly well delineated. However, there
are concerns that these mechanisms of action may result in
deleterious effects in specific clinical contexts.
Hypercapnia and protective lung ventilation
There is an increasing body of evidence in the critical care
literature attesting to the safety of hypercapnic acidosis in
patients undergoing permissive hypercapnia [18,19,76–81].
Furthermore, the potential for hypercapnia to protect against
the deleterious effects of mechanical ventilation is clear. The
potential for hypercapnia to attenuate to the deleterious
effects of high stretch mechanical ventilation in the clinical
context has recently received strong support in a preliminary
report from Kregenow and coworkers [82], in which those
investigators examined mortality as a function of permissive
hypercapnia in patients enrolled in the ARDSnet tidal volume
study [2]. Using multivariate logistic regression analysis, and
controlling for other comorbidities and severity of lung injury,
they reported that, in the high tidal volume arm of the study,
permissive hypercapnia was an independent predictor of
survival. However, there was no additional protective effect of
permissive hypercapnia in patients randomly assigned to
receive the lower tidal volume (6 ml/kg) [82].
At present, there are insufficient clinical data to suggest that
hypercapnia per se should be independently induced, outside
the context of a protective ventilatory strategy. Ventilatory
strategies that involve hypercapnia are clinically acceptable
only provided that the clinician is primarily targeting reduced
tidal stretch. In fact, the recent questioning of the real benefit
of low (versus moderate) tidal volume ventilation for adults
with ARDS may result in hypercapnia becoming less
acceptable in the ventilatory management of ARDS, in the
absence of proven beneficial effects in this context.
Hypercapnia and haemodynamic stability
The potential for hypercapnic acidosis to exert significant
haemodynamic effects in patients with ARDS is clear [83].
However, the potential for hypercapnic acidosis to exert
detrimental effects on myocardial function [84] and on the
peripheral circulation [85] may be overstated. Hypercapnic
acidosis, even when rapidly induced, has been demonstrated
not to produce significant haemodynamic disturbances
[83,85]. Hypercapnic acidosis has repeatedly been demon-
strated to increase cardiac output in ARDS patients [80,83].
In a small but carefully conducted clinical study, the rapid
induction of a hypercapnic acidosis (PaCO2 80 mmHg,
pH 7.2) did impair myocardial contractility, as evaluated with
echocardiography [83]. However, cardiac output was
significantly increased despite impairment in contractility,
presumably as a result of a proportionately greater fall in
systemic vascular resistance. These findings are supported
by a study that evaluated the haemodynamic effects of the
apnoea test for brain-stem function [85]. A 10-min apnoea
test for brain death, which resulted in a mean pH of
7.17 ± 0.02 and mean PaCO2 of 78 ± 3 mmHg, produced
minimal haemodynamic effects in these patients. The safety
of hypercapnic acidosis is further supported by reports that
individuals, both adults [86] and children [87] have survived
exposure to extreme levels.
Nevertheless, at higher levels of hypercapnia and acidosis,
haemodynamic instability may become a limiting factor. This is
supported by experimental evidence demonstrating that animal
survival following mesenteric ischaemia/reperfusion was better
when the inspired carbon dioxide was set at 5% rather than at
10% or 20% [28]. Mortality in these animals resulted from
severe haemodynamic instability after mesenteric reperfusion at
higher inspired carbon dioxide levels.
Hypercapnia in sepsis
Significant concerns have been raised regarding the safety of
hypercapnia in the context of sepsis [29,88,89]. The
importance of these concerns is clear given the prevalence of
sepsis as a cause of admission to the intensive care unit [90],
the frequency of nosocomial infection in the critically ill [91]
and the fact that severe sepsis associated with multiorgan
failure remains a leading cause of death in these patients
[32]. Laboratory studies of hypercapnic acidosis to date have
been in sterile, nonsepsis models of ALI and systemic organ
injury [89]. Although hypercapnic acidosis has been shown to
be protective against endotoxin-induced lung injury [29], this
pathway is only one of several mechanisms by which live
proliferating bacteria cause lung injury.
Hypercapnia and/or acidosis may modulate the interaction
between host and bacterial pathogen via several
mechanisms, as discussed above. The potent anti-
inflammatory properties of hypercapnic acidosis may impair
the host response to live bacterial sepsis. The potential for
hypercapnia to alter intracellular pH regulation may inhibit
neutrophil microbicidal [63,64] and chemotactic activity [92].
The production of free radicals such as the superoxide
radical, hydrogen peroxide and hypochlorous acid are central
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to the bactericidal activity of neutrophils and macrophages.
The potential for hypercapnic acidosis to attenuate free
radical production is clear. This is of importance given that
the phagocytic activity and bactericidal capacity of
neutrophils and macrophages is central to an effective host
response to invading bacteria. Acidosis may render some
antibiotics less effective [93]. In addition, acidosis may alter
the mechanism of neutrophil cell death from apoptosis to
necrosis, which may result in increased tissue destruction
[54,94]. Conversely, hypercapnia may retard pathogen
growth, and thereby decrease the overall septic insult
[95,96]. At the cellular level, mitochondrial dysfunction and
cellular dysoxia are central to the pathogenesis of sepsis
[97,98]. Hypercapnia might favourably modulate cellular
supply–demand balance in favour of cellular survival, given its
effects in other contexts [99]. However, the potential
interactions between hypercapnia and sepsis at the cellular
level remain to be elucidated.
The overall effect of the degree of hypercapnia seen with
protective lung ventilation on the host response to sepsis
remains unclear. Many in vitro studies examining the effects
of carbon dioxide on indices of immune function utilize levels
well beyond that seen in the clinical context. Nevertheless,
the potential for hypercapnia to exert deleterious effects in
the context of sepsis, and to result in significant adverse
consequences, is clear.
Buffering of permissive hypercapnia
Buffering of the acidosis induced by hypercapnia in ARDS
patients remains a common albeit controversial clinical
practice [100,101] and was permitted in the ARDSnet study
[2]. However, there are no long-term clinical outcome data
(e.g. survival, duration of hospital stay) to support the
buffering of a hypercapnic acidosis, and several concerns
exist regarding this practice. There is evidence that the
protective effects of hypercapnic acidosis in ALI are a
function of the acidosis rather than of elevated carbon dioxide
per se [25,45]. Specific concerns exist regarding the use of
bicarbonate to buffer the acidosis produced by hypercapnia.
The effectiveness of bicarbonate infusion as a buffer is
dependent on the ability to excrete carbon dioxide, rendering
it less effective in buffering a hypercapnic acidosis. In fact,
bicarbonate may further raise systemic carbon dioxide levels
under conditions of reduced alveolar ventilation, such as
ARDS [102]. Furthermore, although bicarbonate may correct
arterial pH, it may worsen an intracellular acidosis because
the carbon dioxide produced when bicarbonate reacts with
metabolic acids diffuses readily across cell membranes,
whereas bicarbonate cannot [103]. Taken together, these
issues suggest that, in the absence of a correction to the
primary problem, buffering a hypercapnic acidosis with
bicarbonate is not likely to be of benefit.
These concerns do not exclude a role for the use of other
buffers, such as the amino alcohol tromethamine (tris-
hydroxymethyl aminomethane [THAM]), in specific situations in
which the physiological effects of hypercapnic acidosis are of
concern. THAM penetrates cells easily and can buffer pH
changes and simultaneously reduce carbon dioxide tension
[104], making it effective in situations where carbon dioxide
excretion is limited, such as ARDS [83]. In clinical studies
THAM has been demonstrated to improve arterial pH and base
deficit, and did not increase PaCO2 tension [83,105]. THAM
administration ameliorated the haemodynamic consequences
and rapidly induced hypercapnic acidosis in a small but
carefully performed clinical study in ARDS patients [83].
Conclusion
Permissive hypercapnia is a central component of current
protective lung ventilatory strategies in the clinical context.
Furthermore, induced hypercapnic acidosis appears to
demonstrate considerable protective effects in several
laboratory models of ALI and systemic organ injury. However,
there are concerns regarding the potential for hypercapnia
and/or acidosis to exert deleterious effects, particularly in the
setting of sepsis, that suggest the need for caution and
further investigation into the effects of hypercapnia in the
clinical context. Furthermore, the acceptability of permissive
hypercapnia may be questioned in the future, given concerns
regarding the real benefit of low (versus moderate) tidal
volume ventilation for adults with ARDS. A clearer
understanding of the effects and mechanisms of action of
hypercapnia and acidosis is essential to facilitate
identification of the optimum response to, and tolerance of,
hypercapnia in the setting of protective ventilator strategies,
and to define more clearly the safety and potential therapeutic
utility of hypercapnia in ARDS.
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